Himbert, Caroline
Hathaway, Cassandra A.
Daniels, Bailee
Salas, Karen
Ashworth, Anjelica
Gigic, Biljana
Lin, Tengda
Viskochil, Richard
Kirchhoff, Anne C.
Grossman, Douglas
Ose, Jennifer
Tward, Jonathan
Scaife, Courtney
Figueiredo, Jane C.
Toriola, Adetunji T.
Beck, Anna
Shibata, David
Gonzalez, Brian D.
Matsen, Cindy
Christenson, Cristina
Ma, Debra S.
Colman, Howard
Hunt, Jason P.
Jones, Kevin B.
Lee, Catherine J.
Larson, Mikaela
Onega, Tracy
Akerley, Wallace L.
Li, Christopher I.
Schneider, Martin
Penedo, Frank J.
Siegel, Erin M.
Tworoger, Shelley S.
Ulrich, Cornelia M. http://orcid.org/0000-0001-7641-059X
Peoples, Anita R. http://orcid.org/0000-0003-3645-3960
Funding for this research was provided by:
national cancer institute (U01CA206110, R01CA211705, R01CA189184, R01CA207371, P30CA042014)
huntsman cancer foundation
Article History
Received: 9 July 2021
Accepted: 28 March 2022
First Online: 12 May 2022
Declarations
:
: Dr. Ulrich has as Executive Director of the Comprehensive Cancer Center at Huntsman Cancer Institute oversight over research funded by several pharmaceutical companies but has not received funding directly herself. Dr. Tward has served on an advisory board and consulted for Myriad Genetics, Inc., Decipher Biosciences, and Boston Scientific; he has received research funding from Bayer for work outside of the present manuscript. Dr. Lee has served on advisory boards and/or consulted for Jazz Pharmaceuticals, Kite Pharma, Kadmon Corporation. Fresenius Kabi, and CareDx; she has received research funding from Incyte for work outside of the present manuscript. Dr. Gonzalez has served on advisory boards and/or consulted for SureMed Compliance, Elly Health, and KemPharm. Other authors declare that they have no conflict of interest.
: The University of Utah Institutional Review Board (IRB) approved this protocol.
: All participants provided written informed consent.
: All authors provided consent to publish this manuscript.
Free to read: This content has been made available to all.